Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
-
ORGANIZATION AMDJ to Draw Up Voluntary Rules for Managing Big Data in Field of Healthcare
October 14, 2015
-
REGULATORY MOF Pitches Reimbursement Rate Cuts for OTC-Switched Ethical Drugs, Submission of Related Bills Eyed in 2017
October 13, 2015
-
REGULATORY TPP Will Have No Impact on Japan’s Universal Care Scheme: Negotiator
October 9, 2015
-
REGULATORY Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
-
REGULATORY 8 Year Biologic Data Protection in TPP Won’t Affect Japan: MHLW Official
October 7, 2015
-
REGULATORY MHLW Looks to Establish Panel to Draft Guidelines for English-Language Inserts
October 6, 2015
-
BUSINESS Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
-
ORGANIZATION Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
-
ORGANIZATION New 3 Price-Band Rule Will Boost Predictability, Foster Healthy Competition: JGA Officials
October 2, 2015
-
REGULATORY Chuikyo Debate Heats Up on Number of Generic Brands, Makers; JGA Floats New 3 Price-Band Rule
October 1, 2015
-
ORGANIZATION “Humanitarian Trials” Not Welcomed but Well-Designed: JPMA Regulatory Chief
September 30, 2015
-
ORGANIZATION Drug Pricing Tomorrow: JMA’s Nakagawa Says Price Maintenance Premium Should Continue as Trial Measure
September 29, 2015
-
REGULATORY Health Policy Bureau Chief Futagawa Tapped for MHLW’s Top Bureaucratic Post
September 28, 2015
-
BUSINESS Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
-
REGULATORY One-Month Lag in Regulatory Filing Accepted for Sakigake Designation
September 24, 2015
-
ORGANIZATION JPMA Reprimands Pfizer over Failure to Report ADRs
September 18, 2015
-
ORGANIZATION JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
-
BUSINESS RaQualia Won’t Rule Out Control by Another Firm, Eyes Black Ink in 2018-2019: CEO
September 16, 2015
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…